Advances in myeloma genetics and prospects for pharmacogenomic testing in multiple myeloma.
Pharmacogenomic studies in multiple myeloma, a neoplasia of clonally expanded malignant bone marrow plasma cells, are helping to set the stage for individualized therapy. Although relatively few in numbers, these studies are already providing new therapeutic targets and avenues for drug discoveries as well as contributing to novel prognostic markers in multiple myeloma. High-throughput mutation screening of the kinome promises to identify further novel targets for therapy. Genetics and gene expression profiling technology have improved molecular-based patient stratification and prognostic staging, expanded knowledge of the molecular mechanism of chemotherapeutic agents, and provided a better understanding of myeloma bone disease. The use of pharmacogenomic strategies in myeloma is thus already changing medical practice.
Claudio
Jaime O
JO
Department of Medical Oncology, Princess Margaret Hospital, Toronto, Ontario, Canada
Stewart
A Keith
AK
D006801:Humans; D015201:Meta-Analysis as Topic; D009101:Multiple Myeloma / Q000175:diagnosis* / Q000188:drug therapy / Q000235:genetics*; D010597:Pharmacogenetics / Q000379:methods* / Q000639:trends*; D011379:Prognosis